Roche and Alnylam Report Topline Ph2 Hypertension Results; ITBMed Initiates Ph2 Siplizumab Study in New Onset T1DM Patients
Two cardiometabolic-related news items have been observed: Roche and Alnylam announced topline results from KARDIA-1, a Ph2 study of zilebesiran for the treatment of hypertension (view press release); and ITBMed initiated a Ph2 exposure-response study evaluating if treatment with siplizumab (TCD601) improves beta-cell function in adults recently diagnosed with T1DM (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.